Atorvastatin + Atorvastatin + Atorvastatin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dyslipidemias
Conditions
Dyslipidemias
Trial Timeline
Aug 1, 2003 → Apr 1, 2004
NCT ID
NCT00647543About Atorvastatin + Atorvastatin + Atorvastatin
Atorvastatin + Atorvastatin + Atorvastatin is a approved stage product being developed by Pfizer for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT00647543. Target conditions include Dyslipidemias.
What happened to similar drugs?
5 of 5 similar drugs in Dyslipidemias were approved
Approved (5) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00645151 | Approved | Completed |
| NCT00645424 | Approved | Completed |
| NCT00647543 | Approved | Completed |
Competing Products
15 competing products in Dyslipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3202328 + Placebo + Atorvastatin + Simvastatin | Eli Lilly | Phase 1 | 29 |
| Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg | Yuhan | Approved | 43 |
| LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC | Eli Lilly | Phase 1 | 29 |
| LY3885125 + Placebo | Eli Lilly | Phase 1 | 21 |
| LY3561774 + Placebo | Eli Lilly | Phase 1 | 29 |
| LY3561774 + Placebo | Eli Lilly | Phase 2 | 35 |
| LY2484595 + Placebo + Atorvastatin | Eli Lilly | Phase 2 | 35 |
| Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| Vupanorsen + Placebo | Pfizer | Phase 2 | 35 |
| Atorvastatin | Pfizer | Approved | 43 |
| GWP42003 + GWP42003 + GWP42004 + Placebo | Jazz Pharmaceuticals | Phase 2 | 32 |
| ARO-APOC3 | Arrowhead Pharmaceuticals | Phase 2 | 32 |
| ARO-ANG3 + sterile normal saline (0.9% NaCl) | Arrowhead Pharmaceuticals | Phase 1 | 26 |